scholarly journals Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period

2006 ◽  
Vol 12 (4) ◽  
pp. 389-396 ◽  
Author(s):  
Steven R. Deitcher ◽  
Craig M. Kessler ◽  
Geno Merli ◽  
James R. Rigas ◽  
Roger M. Lyons ◽  
...  
Keyword(s):  
Secondary Prevention ◽  
International Normalized Ratio ◽  
Minor Bleeding ◽  
Thromboembolic Events ◽  
Bleeding Events ◽  
Daily Group ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic ◽  
Subcutaneous Enoxaparin ◽  
Group 2

This study evaluated enoxaparin alone versus initial enoxaparin followed by warfarin in secondary prevention of venous thromboembolic events in adults with active malignancy. Cancer patients (n = 122) with acute symptomatic venous thromboembolic events were randomly allocated to receive subcutaneous enoxaparin 1.0 mg/kg every 12 hours for 5 days, followed by 1.0 mg/kg daily (group 1a) or 1.5 mg/kg daily (group 1b) for 175 days, or subcutaneous enoxaparin 1.0 mg/kg every 12 hours for at least 5 days and until a stable international normalized ratio of 2 to 3 was achieved on oral warfarin begun on day 2 and continued to day 180 (group 2). There were no significant differences in major and minor bleeding rates between treatment groups. No bleeding events were intracranial or fatal. Enoxaparin treatment was feasible, generally well tolerated, and effective for a 180-day period in the secondary prevention of venous thromboembolic events in patients with active malignancy.

scholarly journals Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis

PLoS ONE ◽  
2019 ◽  
Vol 14 (4) ◽  
pp. e0214134 ◽  
Author(s):  
Vicky Mai ◽  
Laurent Bertoletti ◽  
Michel Cucherat ◽  
Sabine Jardel ◽  
Claire Grange ◽  
...  
Keyword(s):  
Secondary Prevention ◽  
Meta Analysis ◽  
Thromboembolic Events ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic

scholarly journals Possible Interaction between Dabigatran and Ranolazine in Patients with Renal Failure

Medicina ◽  
2019 ◽  
Vol 56 (1) ◽  
pp. 13 ◽  
Author(s):  
Gintautas Gumbrevičius ◽  
Gytė Damulevičienė ◽  
Vaidotas Galaunė ◽  
Milda Gumbrevičiūtė
Keyword(s):  
Renal Failure ◽  
Creatinine Clearance ◽  
Dabigatran Etexilate ◽  
International Normalized Ratio ◽  
Thrombin Inhibitor ◽  
Thromboembolic Events ◽  
Treatment And Prevention ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic ◽  
Adequate Dosage

Dabigatran etexilate is a direct oral anticoagulant (thrombin inhibitor) used for the prevention of stroke and systemic thromboembolic events in patients with permanent atrial fibrillation; prevention of venous thromboembolic events and deep veins thrombosis; treatment and prevention of pulmonary embolism. Dabigatran is a relatively new drug, and as a result, its interactions with other medications and their significance are not fully known. A 72 years old male, having a medical history of heart and renal failure, was hospitalized for pneumonia treatment. The patient was taking several drugs, including dabigatran 150 mg twice daily and ranolazine 750 mg twice daily. His creatinine clearance was 45.22 mL/min, International Normalized Ratio (INR)—7.03. Dabigatran was discontinued. After 9 days, INR decreased to 1.33, and after 6 days, creatinine clearance increased to 64.39 mL/min. The patient was taking an adequate dosage of dabigatran, thus dabigatran was thought to be overdosed due to its interaction with ranolazine because dabigatran is a p-glycoprotein substrate, whereas ranolazine is the inhibitor of this transporter. Dabigatran and ranolazine should be used with caution in patients with renal failure. It is recommended to use smaller doses of both medications and observe coagulation parameters if needed.

scholarly journals Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis

2022 ◽  
Author(s):  
Jonas Wagner ◽  
Henrike Wruck ◽  
Anne Lautenbach ◽  
Philipp von Kroge ◽  
Stefan Wolter ◽  
...  
Keyword(s):  
Bariatric Surgery ◽  
Factor Xa ◽  
Secondary Outcome ◽  
Bleeding Events ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic ◽  
Male Patients ◽  
Group 2 ◽  
Reasonable Choice ◽  
Complications After Bariatric Surgery

Abstract Purpose Venous thromboembolic events (VTEs) are common complications after bariatric surgery, and enoxaparin is commonly used to prevent VTEs. The risk for VTEs is sex-specific. Whether enoxaparin application results in similar anti-factor Xa activities (aFXa) in males and females with obesity remains to be determined. We investigated whether our dosage regimen of enoxaparin resulted in similar serum aFXa levels in female and male patients undergoing bariatric surgery. Materials and Methods We administered enoxaparin twice daily in patients undergoing bariatric surgery. Patients with a body mass index (BMI) > 60 kg/m2 (n = 11) received 60 mg enoxaparin (group 2), and patients with lower BMI (n = 86) received 40 mg per dose (group 1). Peak aFXa levels were measured 3 days after surgery. The primary outcome was the aFXa level. As a secondary outcome, we detected VTEs and major bleeding events and explored the possible influencing factors of aFXa. Results Women had higher aFXa than men, but after matching for anthropometric values, the two groups were similar (females: 0.17 ± 0.08 U/ml; males: 0.18 ± 0.08 U/ml). Linear regression revealed a moderate relationship between weight and aFXa levels. The 3-month follow-up was attended by 94.9%, at which one patient had pulmonary embolism. Conclusion Individual enoxaparin dosage regimens for men and women do not seem to be required. Weight-based dosing regimen seems to be a more reasonable choice. Graphical abstract

scholarly journals Recurrence of Upper Extremity Deep Vein Thrombosis Secondary to COVID-19

Viruses ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 878
Author(s):  
Yesha H. Parekh ◽  
Nicole J. Altomare ◽  
Erin P. McDonnell ◽  
Martin J. Blaser ◽  
Payal D. Parikh
Keyword(s):  
Deep Vein Thrombosis ◽  
Lower Extremity ◽  
Upper Extremity ◽  
Thromboembolic Events ◽  
Vein Thrombosis ◽  
Venous Thromboembolic Events ◽  
Venous Thromboembolic ◽  
Deep Vein

Infection with SARS-CoV-2 leading to COVID-19 induces hyperinflammatory and hypercoagulable states, resulting in arterial and venous thromboembolic events. Deep vein thrombosis (DVT) has been well reported in COVID-19 patients. While most DVTs occur in a lower extremity, involvement of the upper extremity is uncommon. In this report, we describe the first reported patient with an upper extremity DVT recurrence secondary to COVID-19 infection.

Sign in / Sign up

Export Citation Format

Share Document